Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18500399 | 0.82 | HDAC8 (0.33) | HDAC8HDAC6ADRA2AADRA2BADRA2C | |
| SCHEMBL21565742 | 0.81 | LMNA (0.42) | GAAHPGDSMN1; SMN2 | |
| SCHEMBL18653145 | 0.77 | GAA (0.30) | GAAHPGDSMN1; SMN2 | |
| SCHEMBL24622795 | 0.74 | — | — | |
| SCHEMBL21323167 | 0.74 | RAPGEF4 (0.37) | SMN1; SMN2 | |
| SCHEMBL10394834 | 0.72 | RAPGEF4 (0.50) | HDAC8HDAC6GAAHPGDSMN1; SMN2 | |
| SCHEMBL18598339 | 0.72 | ADRA2A (0.39) | HDAC8HDAC6ADRA2AADRA2BADRA2C | |
| SCHEMBL21916424 | 0.70 | HDAC8 (0.33) | HDAC8HDAC6ADRA2AADRA2BADRA2C | |
| SCHEMBL24059613 | 0.70 | ESR1 (0.41) | HDAC8HDAC6GAAHPGDSMN1; SMN2 | |
| SCHEMBL18937422 | 0.69 | MAPT (0.50) | GAAHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024907-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024907-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | HDAC8 2505/4885HDAC6 621/4885ADRA2A 4470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.